<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969787</url>
  </required_header>
  <id_info>
    <org_study_id>DWP05195-P001</org_study_id>
    <nct_id>NCT00969787</nct_id>
  </id_info>
  <brief_title>DWP05195 in Healthy Adult Male Volunteers</brief_title>
  <official_title>DWP05195 in Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and
      pharmacodynamics of orally administrated DWP05195 in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Safety &amp; tolerability: Adverse events, vital signs, 12-Lead ECG, laboratory safety variables and physical examination</measure>
    <time_frame>72hr after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax, tmax, AUC, and t½ in plasma / amount of drug, fraction, and CLr in urine Pharmacodynamics: Thermal NeuroSensory Analyser</measure>
    <time_frame>72 hr after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DWP05195</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP05195</intervention_name>
    <description>tablets, oral administration, single and multiple administrations</description>
    <arm_group_label>DWP05195</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male subjects aged 20 to 45 years

          -  The subject has a Body weight ≥ 50 kg and &lt; 90 kg and Body Mass Index (BMI) ≥ 19.0
             kg/m2 and &lt; 27.0 kg/m2

          -  A subject who provided written informed consent to participate in this study and
             cooperative with regard to compliance with study related constraints

          -  A Subject who was judged to be healthy by the investigator to participate in this
             study based on screening results (according to standard reference index updated
             recently)

        Exclusion Criteria:

          -  A subject with sign or symptoms or previously diagnosed disease of respiratory,
             cardiovascular, endocrinology, liver, kidney, gastrointestinal, hematology, neurology
             and psychology function or other significant diseases and history or suspicion of
             current drug abuse and alcohol abuse

          -  A subject who had any allergic history to any drug (prescription drug or OTC
             medication etc.)

          -  A subject who had received treatment with below listed drug within specified period
             prior to the first dose of study medication

               -  Within last 1 month: drug or food known CYP1A2 inducer or inhibitor

               -  Within 2 weeks: Prescribed or herbal or Non-prescribed medicine

               -  Within 3 days: Consumption of grapefruit juice/grapefruit containing products or
                  orange juice/orange containing products, garlic extracted functional foods

               -  Within 3 days: Consumption of alcohol or caffeine

          -  A subject who had participated in any other clinical study within the last 12 weeks

          -  A subject from whom over 400mL of blood was sampled(whole blood or plasma donation,
             etc.) within last 12 weeks

          -  A Subject with the known evidence of the following infections or drug abuse

          -  HIV, HBs, HCV

          -  cannabinoid, opioid, amphetamine, cocaine, barbiturate, benzodiazepine

          -  Smoker or smoking cessation within 1 month or ex-smoker with positive results by
             cotinine test

          -  AST or ALT greater than 1.5 times the upper limit of reference range or QTc &gt; 430 msec
             base on screening results

          -  Blood pressure: SBP ≥ 140 mmHg, DBP ≤ 85 mmHg

          -  A subject judged ineligible by the investigator to participate in this study for other
             reason containing clinical laboratory tests
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2009</study_first_posted>
  <last_update_submitted>March 31, 2010</last_update_submitted>
  <last_update_submitted_qc>March 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Daewoong Pharmaceutical Co. LTD.</name_title>
    <organization>Daewoong Pharmaceutical Co. LTD</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

